• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

炎症性肠病现代治疗时代患者关切问题的研究

A Study of Patient Concerns in the Modern Therapeutic Era of Inflammatory Bowel Disease.

作者信息

Gsenger Victoria, Rodriguez Adriana, Araka Elizabeth, Oza Fouzia, Eskarous Hany, Kochar Bharati, Ananthakrishnan Ashwin N

机构信息

Paracelsus Medical University Salzburg, Strubergasse 21, 5020 Salzburg, Austria.

Division of Gastroenterology, Massachusetts General Hospital-Crohn's and Colitis Center, 165 Cambridge Street, 9th Floor, Boston, MA 02114, USA.

出版信息

Inflamm Bowel Dis. 2025 Jun 13;31(6):1595-1604. doi: 10.1093/ibd/izae197.

DOI:10.1093/ibd/izae197
PMID:39190809
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12166304/
Abstract

BACKGROUND

Patient concerns and preferences are important in the management of inflammatory bowel disease (IBD: Crohn's disease [CD], ulcerative colitis). In the absence of contemporary data, we aimed to determine patient concerns and preferences and establish if there are demographic or disease-related differences.

METHODS

We surveyed patients with IBD at Massachusetts General Hospital between July and September 2023. The Rating Form of Inflammatory Bowel Disease Patient Concerns (RFIPC) and a set of supplemental questions rated on a visual analog scale (0-100 mm) were administered to patients and compared by age, disease type, sex, and surgery status. Additionally, a survey administered to treating providers gathered insight into the difference between patient and provider perceptions of concerns.

RESULTS

A total of 350 patients and 30 providers completed the survey. The mean age was 47 years; 50% were female, 49% had CD, and 80% were on advanced IBD therapy. Effects of medication (median = 54), energy level (median = 53), and having an ostomy bag (median = 52) were rated highest by patients. Older patients rated most disease complication and treatment-related concerns similar to younger adults; those aged 35-59 years had the greatest level of concern for most questions. Sex, disease activity, and prior surgical history also impacted patients' concerns. Providers perceived patients' worries as higher than those rated by patients themselves.

CONCLUSIONS

A shared decision-making model targeting the achievement of disease remission and addressing concerns rated highly by patients is important to meet the goal of care for patients with IBD.

摘要

背景

患者的担忧和偏好对于炎症性肠病(IBD:克罗恩病[CD]、溃疡性结肠炎)的管理至关重要。在缺乏当代数据的情况下,我们旨在确定患者的担忧和偏好,并确定是否存在人口统计学或疾病相关差异。

方法

我们于2023年7月至9月对马萨诸塞州总医院的IBD患者进行了调查。向患者发放了炎症性肠病患者担忧评分表(RFIPC)以及一组基于视觉模拟量表(0-100毫米)评分的补充问题,并按年龄、疾病类型、性别和手术状态进行比较。此外,对治疗提供者进行的一项调查收集了有关患者和提供者对担忧认知差异的见解。

结果

共有350名患者和30名提供者完成了调查。平均年龄为47岁;50%为女性,49%患有CD,80%接受晚期IBD治疗。患者对药物影响(中位数=54)、能量水平(中位数=53)和佩戴造口袋(中位数=52)的评分最高。老年患者对大多数疾病并发症和治疗相关担忧的评分与年轻成年人相似;35-59岁的患者对大多数问题的担忧程度最高。性别、疾病活动度和既往手术史也影响患者的担忧。提供者认为患者的担忧程度高于患者自己的评分。

结论

建立一个以实现疾病缓解和解决患者高度关注问题为目标的共同决策模型,对于实现IBD患者的护理目标很重要。

相似文献

1
A Study of Patient Concerns in the Modern Therapeutic Era of Inflammatory Bowel Disease.炎症性肠病现代治疗时代患者关切问题的研究
Inflamm Bowel Dis. 2025 Jun 13;31(6):1595-1604. doi: 10.1093/ibd/izae197.
2
Impact of moderate-to-severe ulcerative colitis and Crohn's disease on sexual activity: United States and European patient perspectives from the communicating needs and features of IBD experiences (CONFIDE) survey.中重度溃疡性结肠炎和克罗恩病对性活动的影响:来自炎症性肠病经历的沟通需求与特征(CONFIDE)调查的美国和欧洲患者观点
Curr Med Res Opin. 2025 Jul 17:1-14. doi: 10.1080/03007995.2025.2530736.
3
Patient Preferences for Treatment Attributes in Inflammatory Bowel Disease: A Discrete Choice Experiment Among Patients in Five Non-Western Countries.炎症性肠病患者对治疗属性的偏好:五个非西方国家患者的离散选择实验
Adv Ther. 2025 Jun 17. doi: 10.1007/s12325-025-03249-w.
4
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
5
Helminth therapy (worms) for induction of remission in inflammatory bowel disease.蠕虫疗法(使用蠕虫)诱导炎症性肠病缓解
Cochrane Database Syst Rev. 2014 Jan 20;2014(1):CD009400. doi: 10.1002/14651858.CD009400.pub2.
6
Interventions for the management of abdominal pain in Crohn's disease and inflammatory bowel disease.干预措施用于克罗恩病和炎症性肠病的腹痛管理。
Cochrane Database Syst Rev. 2021 Nov 29;11(11):CD013531. doi: 10.1002/14651858.CD013531.pub2.
7
Patient education interventions for the management of inflammatory bowel disease.炎症性肠病管理的患者教育干预措施。
Cochrane Database Syst Rev. 2023 May 4;5(5):CD013854. doi: 10.1002/14651858.CD013854.pub2.
8
Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study.维多珠单抗用于儿童炎症性肠病的维持治疗(VEDOKIDS):一项多中心、前瞻性队列研究的54周结果
Lancet Gastroenterol Hepatol. 2025 Mar;10(3):234-247. doi: 10.1016/S2468-1253(24)00319-4. Epub 2025 Jan 6.
9
Falls prevention interventions for community-dwelling older adults: systematic review and meta-analysis of benefits, harms, and patient values and preferences.社区居住的老年人跌倒预防干预措施:系统评价和荟萃分析的益处、危害以及患者的价值观和偏好。
Syst Rev. 2024 Nov 26;13(1):289. doi: 10.1186/s13643-024-02681-3.
10
Withdrawal of immunosuppressant or biologic therapy for patients with quiescent Crohn's disease.对病情缓解的克罗恩病患者停用免疫抑制剂或生物疗法。
Cochrane Database Syst Rev. 2018 May 12;5(5):CD012540. doi: 10.1002/14651858.CD012540.pub2.

引用本文的文献

1
Genetically-programmed Hypervesiculation of Increases Production of Bacterial Extracellular Vesicles with Therapeutic Efficacy in a Preclinical Inflammatory Bowel Disease Model.基因编程的高囊泡化增加细菌细胞外囊泡的产生,在临床前炎症性肠病模型中具有治疗效果。
bioRxiv. 2025 Jun 25:2025.06.20.660770. doi: 10.1101/2025.06.20.660770.
2
Existential Reflections by Older Adults With Inflammatory Bowel Diseases on Medical and Surgical Treatments.炎症性肠病老年患者对药物及手术治疗的存在主义思考
Am J Gastroenterol. 2025 Apr 7;120(8):1829-1838. doi: 10.14309/ajg.0000000000003475.
3
Interprofessional approach to personalized medication management and therapy optimization in IBD care.炎症性肠病护理中个性化药物管理和治疗优化的跨专业方法。
Front Med (Lausanne). 2025 Jan 29;12:1446695. doi: 10.3389/fmed.2025.1446695. eCollection 2025.

本文引用的文献

1
Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases.Janus 激酶抑制剂在炎症性肠病中的安全性。
Drugs. 2023 Mar;83(4):299-314. doi: 10.1007/s40265-023-01840-5. Epub 2023 Mar 13.
2
Translation and evaluation of the simplified Chinese version of the rating form of IBD patient concerns.炎症性肠病患者关注量表简体中文版的翻译与评价。
BMC Gastroenterol. 2022 Sep 22;22(1):426. doi: 10.1186/s12876-022-02503-7.
3
Is it time to include older adults in inflammatory bowel disease trials? A call for action.是否到了将老年人纳入炎症性肠病临床试验的时候了?呼吁采取行动。
Lancet Healthy Longev. 2022 May;3(5):e356-e366. doi: 10.1016/S2666-7568(22)00060-5. Epub 2022 May 4.
4
Shared decision-making in the management of patients with inflammatory bowel disease.炎症性肠病患者管理中的共同决策。
World J Gastroenterol. 2022 Jul 14;28(26):3092-3100. doi: 10.3748/wjg.v28.i26.3092.
5
Comorbidity Influences the Comparative Safety of Biologic Therapy in Older Adults With Inflammatory Bowel Diseases.合并症影响生物治疗在老年炎症性肠病患者中的相对安全性。
Am J Gastroenterol. 2022 Nov 1;117(11):1845-1850. doi: 10.14309/ajg.0000000000001907. Epub 2022 Aug 12.
6
Systematic Review of Inclusion and Analysis of Older Adults in Randomized Controlled Trials of Medications Used to Treat Inflammatory Bowel Diseases.用于治疗炎症性肠病的药物随机对照试验中纳入和分析老年人的系统评价
Inflamm Bowel Dis. 2021 Aug 19;27(9):1541-1543. doi: 10.1093/ibd/izab052.
7
International Perspectives on Management of Inflammatory Bowel Disease: Opinion Differences and Similarities Between Patients and Physicians From the IBD GAPPS Survey.国际视角下炎症性肠病的管理:IBD GAPPS 调查中患者和医生的意见差异和相似性。
Inflamm Bowel Dis. 2021 Nov 15;27(12):1942-1953. doi: 10.1093/ibd/izab006.
8
Assessing Patient Decision-Making on Biologic and Small-Molecule Therapies in Inflammatory Bowel Diseases: Insights From a Conjoint Analysis in the United States, Canada, and the United Kingdom.评估炎症性肠病患者对生物制剂和小分子治疗药物的决策:来自美国、加拿大和英国的联合分析见解。
Inflamm Bowel Dis. 2021 Oct 18;27(10):1593-1601. doi: 10.1093/ibd/izaa311.
9
The Effect of Psychotherapy on Quality of Life in IBD Patients: A Systematic Review.心理治疗对炎症性肠病患者生活质量的影响:系统评价。
Inflamm Bowel Dis. 2021 Apr 15;27(5):711-724. doi: 10.1093/ibd/izaa144.
10
Head-to-head trials in inflammatory bowel disease: past, present and future.炎症性肠病的头对头试验:过去、现在和未来。
Nat Rev Gastroenterol Hepatol. 2020 Jun;17(6):365-376. doi: 10.1038/s41575-020-0293-9. Epub 2020 Apr 17.